CD1-restricted T Cells in Host Defense to Infectious Diseases
Overview
Microbiology
Authors
Affiliations
CD1 has been clearly shown to function as a microbial recognition system for activation of T cell responses, but its importance for mammalian protective responses against infections is still uncertain. The function of the group 1 CD1 isoforms, including human CD1a, CDlb, and CDLc, seems closely linked to adaptive immunity. These CD1 molecules control the responses of T cells that are highly specific for particular lipid antigens, the best known of which are abundantly expressed by pathogenic mycobacteria such as Mycobacterium tuberculosis and Mycobacterium leprae. Studies done mainly on human circulating T cells ex vivo support a significant role for group I CD1-restricted T cells in protective immunity to mycobacteria and potentially other pathogens, although supportive data from animal models is currently limited. In contrast, group 2 CD1 molecules, which include human CD1d and its orthologs, have been predominantly associated with the activation of CD1d-restricted NKT cells, which appear to be more appropriately viewed as a facet of the innate immune system. Whereas the recognition of certain self-lipid ligands by CD d-restricted NKT cells is well accepted, the importance of these T cells in mediating adaptive immune recognition of specific microbial lipid antigens remains controversial. Despite continuing uncertainty about the role of CD 1d-restricted NKT cells in natural infections, studies in mouse models demonstrate the potential of these T cells to exert various effects on a wide spectrum of infectious diseases, most likely by serving as a bridge between innate and adaptive immune responses.
Liu Q, Liu H, Hu Z, Zhou X, Jin K, Huang Y J Inflamm Res. 2024; 17:3159-3171.
PMID: 38774448 PMC: 11107935. DOI: 10.2147/JIR.S459706.
Walker E, Merino K, Slisarenko N, Grasperge B, Mehra S, Roy C Front Immunol. 2023; 13:1085786.
PMID: 36726992 PMC: 9885173. DOI: 10.3389/fimmu.2022.1085786.
Zhao L, Yang X Front Immunol. 2022; 13:837767.
PMID: 35185930 PMC: 8850912. DOI: 10.3389/fimmu.2022.837767.
Farokhpour F, Rajabi P, Abtahi Naeini B, Naimi A Am J Clin Exp Immunol. 2021; 10(2):56-62.
PMID: 34584778 PMC: 8449155.
Vγ9Vδ2 T Cells: Can We Re-Purpose a Potent Anti-Infection Mechanism for Cancer Therapy?.
Kunkele K, Wesch D, Oberg H, Aichinger M, Supper V, Baumann C Cells. 2020; 9(4).
PMID: 32235616 PMC: 7226769. DOI: 10.3390/cells9040829.